New ECTR Blade Assembly from Hand Biomechanics Lab Could Save up to $10,000 Per Surgeon/Per Year

Hand Biomechanics Lab Returns to the ECTR Market

Hand Biomechanics Lab returns to the ECTR market with a new, drop-in replacement Disposable Blade Assembly for use with the 3M™ Agee Inside Job or MicroAire SmartRelease® systems. The device is a transparent swap for the popular pistol grip system that was developed by HBL founder, Dr. John Agee. Through a collaboration with the orthopedic division of 3M, Dr. Agee and 3M were first to market under patent in 1990.

“We were first to develop and market this system, now we’re first to reduce the cost,” states Dustin Dequine, CFO of HBL. The New ECTR Blade Assembly works with the MicroAire or 3M systems available at many hospitals and surgery centers nationwide. “Our goal is to bring cost savings to this segment as we continue to work to improve patient outcomes,” said Mr. Dequine.

HBL sells the ECTR Disposable Blade Assembly as a 6 pack for $545. The current standard device sold in a 6 pack is priced around $1,140 according to the public, published pricing charged to the Veteran’s Administration. In other words, the HBL Blade Assembly will sell for about half of the current standard pricing. A typical surgeon performs 100 ECTR procedures annually, so HBL’s new device could save the facility as much as $10,000 per year.

Christopher Wilson, MD of Hand Surgery Associates in Sacramento CA, performed a cadaver session with the new device and states, “The HBL Blade Assembly is essentially the same as the current device, but at a substantially lower cost, so it just makes sense.”

Despite the lower cost, the new device is nothing short of the highest quality. The probe itself is injection molded from a medical grade high-performance semi-crystalline thermoplastic. Compared with the current “standard”, the new device offers increased stiffness for improved tactile feel and a wider viewing area with less instrumentation in the field of view for improved visibility of soft tissues.

HBL has designed and patented unique medical devices that have been sold in the US for more than 30 years, and continues to work toward the development of new products for the benefit of patient care.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”